- Regeneration of the specific T-cell response: -> through effector T-cell therapies and through Treg therapies in both autologous and allogeneic settings, with and without genetic optimization, based on a broadly applicable technology platform
Cell Therapy and Personalized Immunosuppression
We focus on the research and development of new advanced therapy medicinal products (ATMPs) from basic research and technology development research through to scientifically rigorous clinical trials. In order to bring these ATMPs to clinical trial, we establish suitable preclinical models (advanced animal models, organ-on-a-chip) and perform comprehensive molecular and functional product characterization as well as process development optimization. This is linked to health economic analyses and biomarker developments.